JP2025506402A5 - - Google Patents
Info
- Publication number
- JP2025506402A5 JP2025506402A5 JP2024546063A JP2024546063A JP2025506402A5 JP 2025506402 A5 JP2025506402 A5 JP 2025506402A5 JP 2024546063 A JP2024546063 A JP 2024546063A JP 2024546063 A JP2024546063 A JP 2024546063A JP 2025506402 A5 JP2025506402 A5 JP 2025506402A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- use according
- gene
- patient
- mcrpc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306801P | 2022-02-04 | 2022-02-04 | |
| US63/306,801 | 2022-02-04 | ||
| EP22162765.6 | 2022-03-17 | ||
| EP22162765 | 2022-03-17 | ||
| US202263330890P | 2022-04-14 | 2022-04-14 | |
| US63/330,890 | 2022-04-14 | ||
| US202263416200P | 2022-10-14 | 2022-10-14 | |
| US63/416,200 | 2022-10-14 | ||
| PCT/EP2023/052718 WO2023148345A1 (en) | 2022-02-04 | 2023-02-03 | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506402A JP2025506402A (ja) | 2025-03-11 |
| JP2025506402A5 true JP2025506402A5 (enExample) | 2026-02-04 |
Family
ID=85150948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024546063A Pending JP2025506402A (ja) | 2022-02-04 | 2023-02-03 | 転移性去勢抵抗性前立腺癌及びｈｒｒ変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン＋プレドニゾン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250170146A1 (enExample) |
| EP (1) | EP4472634A1 (enExample) |
| JP (1) | JP2025506402A (enExample) |
| KR (1) | KR20240148328A (enExample) |
| AU (1) | AU2023214795A1 (enExample) |
| CA (1) | CA3243120A1 (enExample) |
| MX (1) | MX2024009626A (enExample) |
| WO (1) | WO2023148345A1 (enExample) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2138618T3 (es) | 1992-03-31 | 2000-01-16 | Btg Int Ltd | Esteroides 17-sustituidos utiles en el tratamiento del cancer. |
| DE60209673T2 (de) * | 2002-10-22 | 2006-09-21 | Rohm And Haas Co. | Tablettenbeschichtung |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| EP2240466B1 (en) | 2008-01-08 | 2015-07-29 | Merck Sharp & Dohme Limited | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| US20150246060A1 (en) * | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
| BR112020015909A2 (pt) * | 2018-02-05 | 2020-12-15 | Tesaro, Inc. | Formulações pediátricas de niraparib e métodos de tratamento pediátrico |
| PH12022552093A1 (en) * | 2020-02-12 | 2023-11-29 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| JP2023524794A (ja) * | 2020-05-08 | 2023-06-13 | ヤンセン ファーマシューティカ エヌ．ベー． | アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置 |
-
2023
- 2023-02-03 JP JP2024546063A patent/JP2025506402A/ja active Pending
- 2023-02-03 US US18/833,519 patent/US20250170146A1/en active Pending
- 2023-02-03 WO PCT/EP2023/052718 patent/WO2023148345A1/en not_active Ceased
- 2023-02-03 CA CA3243120A patent/CA3243120A1/en active Pending
- 2023-02-03 MX MX2024009626A patent/MX2024009626A/es unknown
- 2023-02-03 KR KR1020247025185A patent/KR20240148328A/ko active Pending
- 2023-02-03 AU AU2023214795A patent/AU2023214795A1/en active Pending
- 2023-02-03 EP EP23702818.8A patent/EP4472634A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI844512B (zh) | 用於治療非轉移性去勢抗性前列腺癌之抗雄性激素 | |
| JP7727543B2 (ja) | ホスホジエステラーゼ阻害剤を含有する放出調節錠剤製剤 | |
| US20250255838A1 (en) | Sustained release compositions of endoxifen | |
| US11065240B2 (en) | Drug combinations to treat multiple myeloma | |
| KR102197465B1 (ko) | 디메틸푸마르산염을 함유한 장용성 정제 | |
| JP7674080B2 (ja) | アビラテロン酢酸エステル含有製剤 | |
| TW202302084A (zh) | 以安森司坦和帕博西尼治療乳癌 | |
| JP2024539476A5 (enExample) | ||
| JP2023525026A5 (enExample) | ||
| US11000481B2 (en) | Composite preparation of mosapride and rabeprazole | |
| CN106999468B (zh) | 熊脱氧胆酸和水飞蓟素改进cpt-11疗效和毒性的制药用途 | |
| JP2025038130A (ja) | エストロゲン受容体アルファ阻害剤の経口剤形を用いて癌を治療する方法 | |
| RU2024125362A (ru) | Нирапариб и абиратерона ацетат плюс преднизон для улучшения клинических результатов у пациентов с метастатическим кастрационно-резистентным раком предстательной железы и изменениями hrr | |
| RU2844940C2 (ru) | Способ лечения рака с помощью пероральной лекарственной формы ингибитора рецептора эстрогена альфа | |
| JP6673798B2 (ja) | カペシタビンを有効成分とするフィルムコート医薬製剤 | |
| JP2025506402A (ja) | 転移性去勢抵抗性前立腺癌及びｈｒｒ変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン＋プレドニゾン | |
| WO2026021460A1 (zh) | 治疗前列腺癌的方法 | |
| HK40116103A (en) | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations | |
| WO2025184497A1 (en) | Stat3 inhibitors for use in the treatment of cancer | |
| HK40115442A (en) | Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate | |
| CN118632695A (zh) | 尼拉帕尼和醋酸阿比特龙加泼尼松用于改善患有转移性去势抵抗性前列腺癌和hrr改变的患者的临床结果 | |
| WO2026021478A1 (zh) | Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法 | |
| WO2021083347A1 (zh) | 喹唑啉衍生物或其盐、或其药物组合物的用途 | |
| WO2008068770A2 (en) | Pharmaceutical composition containing bicalutamide and a method for its use |